35 results
DEFA14A
ACGN
Aceragen Inc
30 Sep 22
Additional proxy soliciting materials
4:18pm
and its Subsidiaries operate, (b) acts of war, armed hostilities or terrorism, acts of God or comparable events, epidemic, pandemic or disease outbreak … affecting the industry in which Parent operates, (b) acts of war, armed hostilities or terrorism, acts of God or comparable events, epidemic, pandemic
8-K
EX-2.1
nsttyishr7f6w5 36
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
o8h88
9 Aug 22
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
4qj1q5 0bs5eo2w08
17 May 22
Idera Pharmaceuticals Shares Positive Results from Investigator- Sponsored Trial in Melanoma Patients at Amsterdam UMC
10:14am
8-K
EX-99.1
nge3do
5 May 22
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
i21f ej22
31 Mar 22
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:20pm
8-K
EX-99.1
501sghyc8qgmauhye a1
14 Dec 21
Idera Pharmaceuticals Announces Tilsotolimod Updates
4:45pm
8-K
3fl3y 1xw
1 Dec 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-99.1
z521r3d
8 Nov 21
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
flwtb2bb
9 Aug 21
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
mlhcrko uqxjwdpt8ol
18 May 21
Idera Pharmaceuticals Announces Corporate Updates
4:41pm